Literature DB >> 24644008

Renal denervation and heart failure.

Michael Böhm1, Sebastian Ewen, Ingrid Kindermann, Dominik Linz, Christian Ukena, Felix Mahfoud.   

Abstract

Renal denervation has been developed in order to lower systolic blood pressure in resistant hypertension by a reduction in renal afferent and efferent sympathetic nerve activity. In heart failure sympathetic activation, in particular, renal norepinephrine release is closely associated with morbidity and mortality. Initial studies have shown that renal denervation is able to reduce not only blood pressure but also heart rate, and is associated with a reduction in myocardial hypertrophy, improved glucose tolerance, and ameliorated microalbuminuria. Since some experimental and observational data suggest an antiarrhythmic effect, it is possible that renal denervation might also play a therapeutic role in arrhythmias often occurring in chronic heart failure. The first proof-of-concept studies are planned to evaluate the clinical effect of this pathophysiologically plausible method, which might be able to change clinical practice.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Hypertension; Renal sympathetic denervation; Sympathetic nervous system

Mesh:

Year:  2014        PMID: 24644008     DOI: 10.1002/ejhf.83

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

Review 1.  Renal Denervation: Where to Now?

Authors:  Neil J Wimmer; Laura Mauri
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

2.  Renal denervation for resistant hypertension: yes.

Authors:  Enrico Boschetti; Yahya Alrashdi; Giuseppe Schillaci
Journal:  Intern Emerg Med       Date:  2016-03-12       Impact factor: 3.397

Review 3.  The acute cardiorenal syndrome: burden and mechanisms of disease.

Authors:  Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 4.  Renal sympathetic denervation for treatment of ventricular arrhythmias: a review on current experimental and clinical findings.

Authors:  Bing Huang; Benjamin J Scherlag; Lilei Yu; Zhibing Lu; Bo He; Hong Jiang
Journal:  Clin Res Cardiol       Date:  2015-01-18       Impact factor: 5.460

Review 5.  Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.

Authors:  Kaushik P Patel; Kenichi Katsurada; Hong Zheng
Journal:  Circ Res       Date:  2022-05-12       Impact factor: 23.213

Review 6.  Integration of renal sensory afferents at the level of the paraventricular nucleus dictating sympathetic outflow.

Authors:  Hong Zheng; Kaushik P Patel
Journal:  Auton Neurosci       Date:  2016-08-06       Impact factor: 3.145

7.  Renal Denervation Improves Exaggerated Sympathoexcitation in Rats With Heart Failure: A Role for Neuronal Nitric Oxide Synthase in the Paraventricular Nucleus.

Authors:  Kaushik P Patel; Bo Xu; Xuefei Liu; Neeru M Sharma; Hong Zheng
Journal:  Hypertension       Date:  2016-05-16       Impact factor: 10.190

8.  Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.

Authors:  Jonathan S Steinberg; Vitaliy Shabanov; Dmitry Ponomarev; Denis Losik; Eduard Ivanickiy; Evgeny Kropotkin; Konstantin Polyakov; Pawel Ptaszynski; Boris Keweloh; Christopher J Yao; Evgeny A Pokushalov; Alexander B Romanov
Journal:  JAMA       Date:  2020-01-21       Impact factor: 56.272

9.  Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial.

Authors:  Jun-Qing Gao; Wei Yang; Zong-Jun Liu
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

Review 10.  Beyond blood pressure: percutaneous renal denervation for the management of sympathetic hyperactivity and associated disease states.

Authors:  Michael J McArdle; Emil M deGoma; Debbie L Cohen; Raymond R Townsend; Robert L Wilensky; Jay Giri
Journal:  J Am Heart Assoc       Date:  2015-03-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.